Earlier, Cleveland Research upgraded Idexx Laboratories to Buy from Neutral. Feedback around new product launches in 2024 “sounds robust” and competitively the firm is seeing Idexx continue to take further share in the U.S. due to bundling and competitor disruption, the analyst told investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IDXX:
- Idexx Laboratories narrows FY23 EPS view to $9.74-$9.90 from $9.64-$9.90
- Idexx Laboratories reports Q3 EPS $2.53 with items, consensus $2.37
- Idexx Laboratories price target lowered to $460 from $500 at Stifel
- Is IDXX a Buy, Before Earnings?
- Idexx Laboratories price target lowered to $520 from $600 at Piper Sandler
